9 results about "Peripheral Artery Diseases" patented technology

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The application discloses a kind of human peripheral blood vessel photoacoustic three-dimensional imaging device and imaging method thereof, belong to blood vessel imaging field.The application provides detailed blood vessel structure and blood flow dynamic information by high resolution and functional monitoring ability of photoacoustic imaging, promote early identification and treatment effect evaluation to common pathological changes such as diabetic foot and peripheral arterial disease;Meanwhile, the application adopts mechanical system, and the detection front end of higher quality can be carried and stably operated, to obtain better photoacoustic imaging result;The application has highly stable precision scanning imaging mode, and various imaging modes are convenient for clinical application;Through the arrangement of imaging tank and its lifting structure, it is ensured that the switching of imaging mode can be applied in limited space, so as to be suitable for gantry type three-dimensional mobile device layout.The application is expected to promote the portability of equipment, reduce equipment development cost, be widely applied in clinical practice and community medical treatment, and improve disease management level.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The present application relates to a DNA drug, a gene targeting delivery system and its application in the treatment of lower extremity peripheral arterial disease. Specifically, the present application relates to a microcrystalline nanocarbon targeted drug delivery system and a plasmid containing human interleukin-4 gene loaded thereon. The delivery system comprises a matrix microcrystalline nanocarbon, and folate, polyethyleneimine and polyethylene glycol modified on the surface thereof. The matrix microcrystalline nanocarbon has a size of 5-20 nanometers, a crystallinity of >80%, a rich mesoporous structure, a high specific surface area and good biocompatibility. The present application also provides a preparation method of the system, which comprises the steps of synthesizing a matrix by pulse modulation radio frequency plasma enhanced chemical vapor deposition, surface functionalization modification and plasmid loading. After injection into the lower extremity muscle, the system can actively target the macrophages in the ischemic site, realize long-term expression of the IL-4 gene at the lesion site. It can effectively promote stable, mature functional angiogenesis by inducing macrophages to polarize to the repair M2 phenotype and regulating the OSM / GSNOR / ENG signal axis, thereby improving limb ischemia. The present application has important application value in the field of gene therapy for ischemic diseases, especially peripheral arterial disease and severe limb ischemia.

Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a cardiovascular disease. Such compound and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a RAAS pathway-related disease or disorder. Such symptoms and hallmarks include hypertension, chronic kidney disease, stroke, myocardial infarction, heart failure, valvular heart disease, aneurysms of the blood vessels, peripheral artery disease, and organ damage. Such cardiovascular diseases include hypertension, resistant hypertension, Marfan syndrome, and heart failure.

This invention relates to substituted pyrazolopiperidine carboxylic acids, their salts and methods of preparation thereof, and also to their use in the preparation of medicaments for the treatment and / or prevention of diseases, particularly cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral artery disease (PAD, PAOD), cardiorenal and renal diseases, preferably chronic kidney disease and diabetic kidney disease (CKD and DKD), cardiopulmonary and pulmonary diseases, preferably pulmonary hypertension (PH) and other diseases, preferably neurodegenerative diseases and different forms of dementia, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), and wound healing disorders such as diabetic foot ulcers (DFU).

The invention relates to an artificial intelligence based, wearable technology-supported telemedicine and remote patient management system for peripheral arterial diseases, which enables patient management by means of remote monitoring and early diagnosis in peripheral arterial diseases, and which ensures the reduction or prevention of complications, mortality and morbidity risks arising from peripheral arterial diseases.

The application provides a peripheral arterial disease patient death risk prediction method and system, the method comprising: acquiring preoperative cross-sectional images of the maximum soft tissue of the lower leg of a plurality of peripheral arterial disease patients; acquiring the lower leg skeletal muscle area of the plurality of peripheral arterial disease patients according to the cross-sectional images; acquiring the lower leg muscle index of the plurality of peripheral arterial disease patients according to the height data and the lower leg skeletal muscle area of the plurality of peripheral arterial disease patients; training a gradient boosting machine model using clinical baseline physiological data, lower leg muscle indexes and postoperative survival data of the plurality of peripheral arterial disease patients as training samples to obtain a death risk prediction model; and predicting the postoperative death risk of a target patient with a target peripheral arterial disease by using the death risk prediction model to obtain death risk prediction results corresponding to a plurality of time nodes after the operation. The application effectively improves the accuracy of obtaining the death risk prediction results at a plurality of time nodes after the operation.